Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20146020 | 0.94 | RECQL (0.34) | KMT2ATSHRMAPTMEN1USP2 | |
| SCHEMBL16035002 | 0.85 | HDAC3 (0.38) | KMT2ATSHRMAPTMEN1USP2 | |
| SCHEMBL8526820 | 0.83 | KMT2A (0.44) | KMT2ATSHRMAPTMEN1USP2 | |
| SCHEMBL9733862 | 0.81 | HSD17B10 (0.37) | KMT2ATSHRMAPTUSP2L3MBTL1 | |
| SCHEMBL16035156 | 0.78 | MEN1 (0.40) | KMT2AMEN1L3MBTL1RAB9A | |
| SCHEMBL8491964 | 0.72 | KMT2A (0.44) | KMT2ATSHRMAPTMEN1USP2 | |
| SCHEMBL16034504 | 0.71 | TAS1R3 (0.32) | KMT2AMAPTMEN1L3MBTL1RAB9A | |
| SCHEMBL16034506 | 0.71 | TAS1R3 (0.32) | KMT2AMAPTMEN1L3MBTL1RAB9A | |
| SCHEMBL17559391 | 0.71 | KMT2A (0.44) | KMT2ATSHRMAPTMEN1USP2 | |
| SCHEMBL587574 | 0.70 | KMT2A (0.44) | KMT2ATSHRMAPTMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851119-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851119-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2020-05-21 | — | — | US | disclosed |
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2020-05-21 | — | — | US | disclosed |
| US-10464951-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2019-11-05 | — | — | US | disclosed |
| US-10464951-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2019-11-05 | — | — | US | disclosed |
| EP-2970106-B1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2018-05-16 | — | — | EP | disclosed |
| US-20180079759-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079759-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079759-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION (US) | 2018-03-22 | — | — | US | disclosed |
| US-20150322092-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322092-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION (US) | 2015-11-12 | — | — | US | disclosed |
| US-9127024-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-9127024-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-9127024-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| WO-2014144380-A1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORPORATION (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140274954-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION | 2014-09-18 | — | — | US | disclosed |
| US-20140274954-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION | 2014-09-18 | — | — | US | disclosed |
| US-20140274954-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION | 2014-09-18 | — | — | US | disclosed |
| US-8623993-B2 | Chemicals and the synthesizing methods thereof | NATIONAL CHAIO TUNG UNIVERSITY (TW) | 2014-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464951-B2 | Boron-containing diacylhydrazines | CD22, BRDT, BCR | KMT2A 1526/4885TSHR 236/4885MAPT 4167/4885 |
| US-20150322092-A1 | Boron-Containing Diacylhydrazines | CD22, BRDT, BCR | KMT2A 1526/4885TSHR 236/4885MAPT 4167/4885 |
| US-10851119-B2 | Boron-containing diacylhydrazines | CD22, BRDT, BCR | KMT2A 1526/4885TSHR 236/4885MAPT 4167/4885 |
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | CD22, BRDT, BCR | KMT2A 1526/4885TSHR 236/4885MAPT 4167/4885 |
| US-20140274954-A1 | Boron-Containing Diacylhydrazines | CD22, BRDT, BCR | KMT2A 1526/4885TSHR 236/4885MAPT 4167/4885 |
| US-20180079759-A1 | Boron-Containing Diacylhydrazines | CD22, BRDT, BCR | KMT2A 1526/4885TSHR 236/4885MAPT 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.